Great Waters Wealth Management Grows Holdings in Johnson & Johnson (NYSE:JNJ)

Great Waters Wealth Management increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,835 shares of the company’s stock after purchasing an additional 108 shares during the quarter. Great Waters Wealth Management’s holdings in Johnson & Johnson were worth $297,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Eclectic Associates Inc. ADV lifted its stake in Johnson & Johnson by 1.2% during the third quarter. Eclectic Associates Inc. ADV now owns 8,236 shares of the company’s stock worth $1,335,000 after purchasing an additional 97 shares during the last quarter. Allied Investment Advisors LLC lifted its stake in Johnson & Johnson by 1.3% during the third quarter. Allied Investment Advisors LLC now owns 61,665 shares of the company’s stock worth $9,993,000 after purchasing an additional 820 shares during the last quarter. Triton Wealth Management PLLC lifted its stake in Johnson & Johnson by 4.5% during the third quarter. Triton Wealth Management PLLC now owns 4,578 shares of the company’s stock worth $741,000 after purchasing an additional 199 shares during the last quarter. Thrive Wealth Management LLC lifted its stake in Johnson & Johnson by 0.8% during the third quarter. Thrive Wealth Management LLC now owns 23,739 shares of the company’s stock worth $3,847,000 after purchasing an additional 189 shares during the last quarter. Finally, AMI Investment Management Inc. lifted its stake in Johnson & Johnson by 4.8% during the third quarter. AMI Investment Management Inc. now owns 23,885 shares of the company’s stock worth $3,871,000 after purchasing an additional 1,090 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several analyst reports. Morgan Stanley increased their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. TD Securities dropped their target price on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Sanford C. Bernstein increased their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, September 30th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Price Performance

JNJ stock traded down $0.21 during trading hours on Friday, hitting $160.29. 5,331,694 shares of the stock traded hands, compared to its average volume of 7,091,981. The stock has a 50-day simple moving average of $162.60 and a 200 day simple moving average of $154.33. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a market cap of $385.77 billion, a P/E ratio of 9.99, a P/E/G ratio of 2.69 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the business posted $2.80 earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.09%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.